Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
$129.46
+0.1%
$119.38
$73.04
$129.65
$8.35B0.891.53 million shs2.98 million shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$14.96
+3.1%
$13.76
$8.02
$15.78
$7.21B1.675.04 million shs5.00 million shs
Indivior PLC stock logo
INDV
Indivior
$16.16
+3.6%
$13.39
$7.33
$16.33
N/A0.651.23 million shs2.13 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$11.65
+1.0%
$11.14
$8.73
$13.06
$7.84B1.155.74 million shs4.46 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
-0.05%+0.57%+0.80%+52.77%+7.29%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-0.69%-1.97%+3.61%+71.83%+9.50%
Indivior PLC stock logo
INDV
Indivior
+1.43%+3.04%+10.01%+73.14%+51.31%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
+1.58%+2.85%+4.15%+13.69%-0.60%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
1.0869 of 5 stars
2.12.00.00.02.30.80.6
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
1.5798 of 5 stars
1.31.00.00.32.01.71.3
Indivior PLC stock logo
INDV
Indivior
1.8457 of 5 stars
1.61.00.00.02.21.73.1
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.6562 of 5 stars
3.63.00.00.02.32.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
2.24
Hold$128.25-0.93% Downside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.63
Moderate Buy$16.006.97% Upside
Indivior PLC stock logo
INDV
Indivior
3.25
Buy$17.005.20% Upside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
3.25
Buy$16.5041.63% Upside

Current Analyst Ratings Breakdown

Latest INDV, BPMC, ROIV, and ELAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$18.00
7/10/2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$19.00
7/2/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$16.00 ➝ $17.00
6/30/2025
Indivior PLC stock logo
INDV
Indivior
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $22.00
6/26/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
6/18/2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00
6/17/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$143.00 ➝ $129.00
6/5/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$102.00 ➝ $129.00
6/5/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$88.00 ➝ $129.00
6/4/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell ➝ Hold$83.00 ➝ $129.00
6/3/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$132.00
(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
$508.82M16.43N/AN/A$4.70 per share27.54
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.44B1.67$2.32 per share6.44$12.33 per share1.21
Indivior PLC stock logo
INDV
Indivior
$1.19BN/A$1.89 per share8.57($2.52) per shareN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$29.05M272.63N/AN/A$7.45 per share1.56
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
-$67.09M-$2.47N/A199.17N/A-27.70%-64.60%-17.22%7/30/2025 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$338M$0.7420.2116.812.838.43%7.54%3.57%8/7/2025 (Estimated)
Indivior PLC stock logo
INDV
Indivior
$2M-$0.31N/A9.45N/A-4.02%-97.29%15.74%7/24/2025 (Estimated)
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$171.98M-$0.25N/AN/AN/A-225.71%-14.76%-13.69%8/6/2025 (Estimated)

Latest INDV, BPMC, ROIV, and ELAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q1 2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.23N/AN/AN/AN/AN/A
8/7/2025Q2 2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
-$0.54N/AN/AN/A$171.34 millionN/A
8/7/2025Q2 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.1989N/AN/AN/A$1.19 billionN/A
7/24/2025Q2 2025
Indivior PLC stock logo
INDV
Indivior
$0.25N/AN/AN/AN/AN/A
5/29/2025Q4 2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.16-$0.31-$0.15-$0.29$62.17 million$7.57 million
5/7/2025Q1 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.31$0.37+$0.06$0.14$1.17 billion$1.19 billion
5/1/2025Q1 2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
-$0.42-$0.74-$0.32$0.01$158.31 million$149.41 million
4/24/2025Q1 2025
Indivior PLC stock logo
INDV
Indivior
$0.22$0.41+$0.19$0.38$240.13 million$266.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Indivior PLC stock logo
INDV
Indivior
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
1.01
2.80
2.75
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.68
2.71
1.46
Indivior PLC stock logo
INDV
Indivior
N/A
0.88
0.72
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
33.47
33.47

Institutional Ownership

CompanyInstitutional Ownership
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
N/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Indivior PLC stock logo
INDV
Indivior
60.33%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%

Insider Ownership

CompanyInsider Ownership
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
4.21%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.89%
Indivior PLC stock logo
INDV
Indivior
N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
7.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
64064.58 million61.86 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,000496.65 million492.23 millionOptionable
Indivior PLC stock logo
INDV
Indivior
1,051N/AN/ANot Optionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
860679.81 million626.10 millionOptionable

Recent News About These Companies

Roivant Sciences Ltd. (ROIV) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Blueprint Medicines stock logo

Blueprint Medicines NASDAQ:BPMC

$129.46 +0.18 (+0.14%)
Closing price 04:00 PM Eastern
Extended Trading
$129.48 +0.02 (+0.02%)
As of 05:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$14.96 +0.45 (+3.08%)
Closing price 03:59 PM Eastern
Extended Trading
$14.92 -0.03 (-0.22%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Indivior stock logo

Indivior NASDAQ:INDV

$16.16 +0.56 (+3.59%)
Closing price 04:00 PM Eastern
Extended Trading
$16.00 -0.16 (-0.96%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$11.65 +0.11 (+0.95%)
Closing price 04:00 PM Eastern
Extended Trading
$11.54 -0.12 (-0.99%)
As of 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.